Charles River Laboratories International (NYSE:CRL) Given New $239.00 Price Target at Robert W. Baird

Charles River Laboratories International (NYSE:CRL) had its price objective decreased by Robert W. Baird from $271.00 to $239.00 in a research note issued to investors on Wednesday, Benzinga reports. Robert W. Baird currently has an outperform rating on the medical research company’s stock.

Several other analysts have also issued reports on the stock. Mizuho initiated coverage on shares of Charles River Laboratories International in a research report on Friday, June 7th. They issued a neutral rating and a $235.00 price target on the stock. Argus restated a hold rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. StockNews.com lowered shares of Charles River Laboratories International from a buy rating to a hold rating in a research report on Friday, June 14th. Barclays initiated coverage on shares of Charles River Laboratories International in a report on Friday, June 28th. They set an equal weight rating and a $230.00 price objective for the company. Finally, TD Cowen reduced their price objective on shares of Charles River Laboratories International from $260.00 to $228.00 and set a hold rating for the company in a report on Monday, May 13th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of Hold and an average target price of $252.29.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $216.22 on Wednesday. Charles River Laboratories International has a 1 year low of $161.65 and a 1 year high of $275.00. The firm’s fifty day simple moving average is $214.47 and its 200 day simple moving average is $230.74. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $11.14 billion, a PE ratio of 25.44, a PEG ratio of 1.92 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. On average, sell-side analysts anticipate that Charles River Laboratories International will post 11 EPS for the current year.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the transaction, the executive vice president now directly owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors have recently added to or reduced their stakes in CRL. VisionPoint Advisory Group LLC raised its stake in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after acquiring an additional 74 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of Charles River Laboratories International in the first quarter worth about $41,000. Brown Brothers Harriman & Co. raised its stake in shares of Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after acquiring an additional 95 shares during the last quarter. GAMMA Investing LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter worth about $62,000. Finally, Bruce G. Allen Investments LLC bought a new position in shares of Charles River Laboratories International in the fourth quarter worth about $70,000. 98.91% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).